<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Modern Therapy in Psychiatry and Neurology Journal</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Modern Therapy in Psychiatry and Neurology Journal</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Современная терапия в психиатрии и неврологии</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2304-9707</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">101268</article-id>
   <article-id pub-id-type="doi">10.32416/2304-9707-2025-2-21-26</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>ПСИХИАТРИЯ</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>PSYCHIATRY</subject>
    </subj-group>
    <subj-group>
     <subject>ПСИХИАТРИЯ</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Efficacy of long-term combination antipsychotic therapy with high-dose clozapine and haloperidol in treatment-resistant continuous paranoid schizophrenia</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Эффективность длительной антипсихотической терапии комбинацией клозапина и галоперидола в высоких дозах при резистентной непрерывной параноидной шизофрении</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Калач</surname>
       <given-names>Анастасия Владимировна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Kalach</surname>
       <given-names>Anastasiya Vladimirovna</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет) Минздрава России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет) Минздрава России</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2025-07-10T18:38:24+03:00">
    <day>10</day>
    <month>07</month>
    <year>2025</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-07-10T18:38:24+03:00">
    <day>10</day>
    <month>07</month>
    <year>2025</year>
   </pub-date>
   <volume>2025</volume>
   <issue>2</issue>
   <fpage>21</fpage>
   <lpage>26</lpage>
   <history>
    <date date-type="received" iso-8601-date="2025-07-10T00:00:00+03:00">
     <day>10</day>
     <month>07</month>
     <year>2025</year>
    </date>
   </history>
   <self-uri xlink:href="https://logospress.editorum.ru/en/nauka/article/101268/view">https://logospress.editorum.ru/en/nauka/article/101268/view</self-uri>
   <abstract xml:lang="ru">
    <p>Описано многолетнее клиническое наблюдение пациента с непрерывной параноидной шизофренией, проявляющейся парафренным синдромом, у которого ослабление психотической симптоматики достигалось при использовании комбинации высоких доз клозапина (600 мг/сут) и галоперидола (60 мг/сут) в сочетании с бромдигидрохлорфенилбензодиазепином (1 мг/сут) в качестве сопутствующей терапии. Представленный случай демонстрирует возможность частичного преодоления терапевтической резистентности при помощи применения указанной терапии и одновременно ее достаточно хорошей индивидуальной переносимости.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>This long-term clinical observation presents a patient with continuous paranoid schizophrenia manifesting as paraphrenic syndrome. A reduction of psychotic symptoms was achieved with a combination of high-dose clozapine (600 mg/day) and haloperidol (60 mg/day) in combination with bromdihydrochlorophenylbenzodiazepine (1 mg/day) as concomitant therapy. This case demonstrates the possibility of partially overcoming treatment resistance through such therapy and its reasonably good individual tolerability.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>шизофрения непрерывная параноидная</kwd>
    <kwd>парафренный синдром</kwd>
    <kwd>терапевтическая резистентность</kwd>
    <kwd>комбинированная антипсихотическая терапия</kwd>
    <kwd>клозапин</kwd>
    <kwd>галоперидол</kwd>
    <kwd>высокие дозы антипсихотических средств</kwd>
    <kwd>типичные антипсихотические средства</kwd>
    <kwd>атипичные антипсихотические средства</kwd>
    <kwd>сопутствующая терапия</kwd>
    <kwd>бромдигидрохлорфенилбензодиазепин</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>continuous paranoid schizophrenia</kwd>
    <kwd>paraphrenic syndrome</kwd>
    <kwd>therapeutic resistance</kwd>
    <kwd>combination antipsychotic therapy</kwd>
    <kwd>clozapine</kwd>
    <kwd>haloperidol</kwd>
    <kwd>high-dose antipsychotics</kwd>
    <kwd>typical antipsychotics</kwd>
    <kwd>atypical antipsychotics</kwd>
    <kwd>concomitant therapy</kwd>
    <kwd>bromdihydrochlorophenylbenzodiazepine</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Терапевтическая резистентность при шизофрении и биологические методы ее преодоления. Журнал неврологии и психиатрии им. С.С.Корсакова. 2008;108(10):81-86.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Terapevticheskaya rezistentnost' pri shizofrenii i biologicheskie metody ee preodoleniya. Zhurnal nevrologii i psihiatrii im. S.S.Korsakova. 2008;108(10):81-86.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Купирующая терапия обострений непрерывной параноидной шизофрении (эффективность клозапина, рисперидона, оланзапина, кветиапина и типичных нейролептиков и ее зависимость от клинических особенностей заболевания). Сибирский вестник психиатрии и наркологии. 2010;3(60):82-88.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Kupiruyuschaya terapiya obostreniy nepreryvnoy paranoidnoy shizofrenii (effektivnost' klozapina, risperidona, olanzapina, kvetiapina i tipichnyh neyroleptikov i ee zavisimost' ot klinicheskih osobennostey zabolevaniya). Sibirskiy vestnik psihiatrii i narkologii. 2010;3(60):82-88.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С., Морозова В.Д. Оптимизация лечебного процесса у больных шизофренией, резистентных к антипсихотической терапии. Российский психиатрический журнал. 2010;(4):75-83.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S., Morozova V.D. Optimizaciya lechebnogo processa u bol'nyh shizofreniey, rezistentnyh k antipsihoticheskoy terapii. Rossiyskiy psihiatricheskiy zhurnal. 2010;(4):75-83.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Малин Д.И. Современный взгляд на эффективность электросудорожной терапии в лечении больных шизофренией. Современная терапия психических расстройств. 2024;(2):14-21.</mixed-citation>
     <mixed-citation xml:lang="en">Malin D.I. Sovremennyy vzglyad na effektivnost' elektrosudorozhnoy terapii v lechenii bol'nyh shizofreniey. Sovremennaya terapiya psihicheskih rasstroystv. 2024;(2):14-21.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Мосолов С.Н., Цукарзи Э.Э., Оленева Е.В., Алфимов П.В. Современные методы преодоления терапевтической резистентности при шизофрении. В кн.: Мосолов С.Н., редактор. Биологические методы терапии психических расстройств. Доказательная медицина – клинической практике. Москва: Социально-политическая мысль; 2012. С. 102-117.</mixed-citation>
     <mixed-citation xml:lang="en">Mosolov S.N., Cukarzi E.E., Oleneva E.V., Alfimov P.V. Sovremennye metody preodoleniya terapevticheskoy rezistentnosti pri shizofrenii. V kn.: Mosolov S.N., redaktor. Biologicheskie metody terapii psihicheskih rasstroystv. Dokazatel'naya medicina – klinicheskoy praktike. Moskva: Social'no-politicheskaya mysl'; 2012. S. 102-117.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Barber S., Olotu U., Corsi M., Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017 Mar;3(3): CD006324. doi: 10.1002/14651858.CD006324.pub3</mixed-citation>
     <mixed-citation xml:lang="en">Barber S., Olotu U., Corsi M., Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017 Mar;3(3): CD006324. doi: 10.1002/14651858.CD006324.pub3</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Samara M., Alevizopoulos G., Bozikas V.P., et al. Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities. Expert Rev Neurother. 2025 Mar;25(5):505-19. doi: 10.1080/14737175.2025.2484434</mixed-citation>
     <mixed-citation xml:lang="en">Samara M., Alevizopoulos G., Bozikas V.P., et al. Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities. Expert Rev Neurother. 2025 Mar;25(5):505-19. doi: 10.1080/14737175.2025.2484434</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Schneider-Thoma J., Hamza T., Chalkou K., et al. Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis. Lancet Psychiatry. 2025 Apr;12(4):254-65. doi: 10.1016/S2215-0366(25)00001-X</mixed-citation>
     <mixed-citation xml:lang="en">Schneider-Thoma J., Hamza T., Chalkou K., et al. Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis. Lancet Psychiatry. 2025 Apr;12(4):254-65. doi: 10.1016/S2215-0366(25)00001-X</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sinclair D.J., Zhao S., Qi F., et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev.2019 Mar;3(3):CD011847. doi: 10.1002/14651858.CD011847.pub2</mixed-citation>
     <mixed-citation xml:lang="en">Sinclair D.J., Zhao S., Qi F., et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev.2019 Mar;3(3):CD011847. doi: 10.1002/14651858.CD011847.pub2</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Wagner E., Borgwardt S., Hasan A. Management of treatment-resistant schizophrenia (article in German). Nervenarzt. 2024 May;95(5):423-31. doi: 10.1007/s00115-024-01608-6</mixed-citation>
     <mixed-citation xml:lang="en">Wagner E., Borgwardt S., Hasan A. Management of treatment-resistant schizophrenia (article in German). Nervenarzt. 2024 May;95(5):423-31. doi: 10.1007/s00115-024-01608-6</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Терапия шизофрении (атипичные нейролептики и индивидуальная организация лечебного процесса). Москва: Миклош; 2010. 320 с.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Terapiya shizofrenii (atipichnye neyroleptiki i individual'naya organizaciya lechebnogo processa). Moskva: Miklosh; 2010. 320 s.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С., Тюльпин Ю.Г. Лечение шизофрении. Москва: Медицинское информационное агентство; 2010. 276 с.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S., Tyul'pin Yu.G. Lechenie shizofrenii. Moskva: Medicinskoe informacionnoe agentstvo; 2010. 276 s.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С., Морозова В.Д., Лукьянова Т.В. Терапевтическая резистентность и методы ее преодоления. В кн.: Иванец НН, редактор. Сборник тезисов Всероссийской юбилейной научно-практической конференции с международным участием «Актуальные проблемы психиатрии». Москва: Первый МГМУ имени И.М. Сеченова; 2012. C. 162-164.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S., Morozova V.D., Luk'yanova T.V. Terapevticheskaya rezistentnost' i metody ee preodoleniya. V kn.: Ivanec NN, redaktor. Sbornik tezisov Vserossiyskoy yubileynoy nauchno-prakticheskoy konferencii s mezhdunarodnym uchastiem «Aktual'nye problemy psihiatrii». Moskva: Pervyy MGMU imeni I.M. Sechenova; 2012. C. 162-164.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Помыткин А.Н. Клинико-биологические аспекты терапевтического ответа на ритмическую транскраниальную магнитную стимуляцию при резистентной шизофрении. Диссертация кандидата медицинских наук. Москва; 2023. 250 с.</mixed-citation>
     <mixed-citation xml:lang="en">Pomytkin A.N. Kliniko-biologicheskie aspekty terapevticheskogo otveta na ritmicheskuyu transkranial'nuyu magnitnuyu stimulyaciyu pri rezistentnoy shizofrenii. Dissertaciya kandidata medicinskih nauk. Moskva; 2023. 250 s.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Galling B., Roldán A., Hagi K., et al. Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017 Feb;16(1):77-89. doi: 10.1002/wps.20387</mixed-citation>
     <mixed-citation xml:lang="en">Galling B., Roldán A., Hagi K., et al. Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017 Feb;16(1):77-89. doi: 10.1002/wps.20387</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kane J.M., Correll C.U. The role of clozapine in treatment-resistant schizophrenia. JAMAPsychiatry. 2016 Mar;73(3):187-8. doi: 10.1001/jamapsychiatry.2015.2966</mixed-citation>
     <mixed-citation xml:lang="en">Kane J.M., Correll C.U. The role of clozapine in treatment-resistant schizophrenia. JAMAPsychiatry. 2016 Mar;73(3):187-8. doi: 10.1001/jamapsychiatry.2015.2966</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Кайдан М.А. Шизофрения, резистентная к антипсихотической терапии (психопатологические особенности, возможности преодоления резистентности). Диссертация кандидата медицинских наук. Москва; 2025. 153 с.</mixed-citation>
     <mixed-citation xml:lang="en">Kaydan M.A. Shizofreniya, rezistentnaya k antipsihoticheskoy terapii (psihopatologicheskie osobennosti, vozmozhnosti preodoleniya rezistentnosti). Dissertaciya kandidata medicinskih nauk. Moskva; 2025. 153 s.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B18">
    <label>18.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Помыткин А.Н., Тихонов Д.В., Каледа В.Г. Аугментация терапии резистентной шизофрении методом ритмической транскраниальной магнитной стимуляции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(8):107-114.</mixed-citation>
     <mixed-citation xml:lang="en">Pomytkin A.N., Tihonov D.V., Kaleda V.G. Augmentaciya terapii rezistentnoy shizofrenii metodom ritmicheskoy transkranial'noy magnitnoy stimulyacii. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2023;123(8):107-114.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B19">
    <label>19.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Становая В.В., Гусейнова З.Т., Иванов М.В., Бигдай Е.В. Феномен терапевтической резистентности при лечении шизофрении: возможности современной диагностики и методов противорезистентных воздействий. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2023;57(4):120-130.</mixed-citation>
     <mixed-citation xml:lang="en">Stanovaya V.V., Guseynova Z.T., Ivanov M.V., Bigday E.V. Fenomen terapevticheskoy rezistentnosti pri lechenii shizofrenii: vozmozhnosti sovremennoy diagnostiki i metodov protivorezistentnyh vozdeystviy. Obozrenie psihiatrii i medicinskoy psihologii im. V.M. Behtereva. 2023;57(4):120-130.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B20">
    <label>20.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Anand R., Turolla A., Chinellato G., et al. Effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final, 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial. Int J Neuropsychopharmacol.2024 Dec;28(1):pyae061. doi: 10.1093/ijnp/pyae061</mixed-citation>
     <mixed-citation xml:lang="en">Anand R., Turolla A., Chinellato G., et al. Effect of evenamide, a glutamate inhibitor, in patients with treatment-resistant schizophrenia (TRS): final, 1-year results from a phase 2, open-label, rater-blinded, randomized, international clinical trial. Int J Neuropsychopharmacol.2024 Dec;28(1):pyae061. doi: 10.1093/ijnp/pyae061</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B21">
    <label>21.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Cipolla S., Delli Carpini F., Catapano P., et al. Two long-acting antipsychotics in a patient with treatment-resistant schizophrenia: A case report. Clin Pract.2025 Mar;15(3):55. doi: 10.3390/clinpract15030055</mixed-citation>
     <mixed-citation xml:lang="en">Cipolla S., Delli Carpini F., Catapano P., et al. Two long-acting antipsychotics in a patient with treatment-resistant schizophrenia: A case report. Clin Pract.2025 Mar;15(3):55. doi: 10.3390/clinpract15030055</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B22">
    <label>22.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Moriarty S.E., Parhami P., Parikh J., Galicki L. Antipsychotic polypharmacy for treatment resistant schizoaffective disorder: A case report. Cureus.2025 Mar;17(3):e80204. doi: 10.7759/cureus.80204</mixed-citation>
     <mixed-citation xml:lang="en">Moriarty S.E., Parhami P., Parikh J., Galicki L. Antipsychotic polypharmacy for treatment resistant schizoaffective disorder: A case report. Cureus.2025 Mar;17(3):e80204. doi: 10.7759/cureus.80204</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B23">
    <label>23.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ochi S., Kodaka F., Hasegawa N., et al. Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study. Int J Neuropsychopharmacol. 2025 Apr;28(4):pyaf011. doi: 10.1093/ijnp/pyaf011</mixed-citation>
     <mixed-citation xml:lang="en">Ochi S., Kodaka F., Hasegawa N., et al. Associations between clozapine availability, the diagnosis of treatment-resistant schizophrenia subgroups, antipsychotic monotherapy, and concomitant psychotropics among patients with schizophrenia: a real-world nationwide study. Int J Neuropsychopharmacol. 2025 Apr;28(4):pyaf011. doi: 10.1093/ijnp/pyaf011</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B24">
    <label>24.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Возможность формирования ремиссии высокого качества при длительном хроническом течении шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(11):80-85.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Vozmozhnost' formirovaniya remissii vysokogo kachestva pri dlitel'nom hronicheskom techenii shizofrenii. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2008;108(11):80-85.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B25">
    <label>25.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Эффективность терапии шизофрении атипичными нейролептиками (значение различных клинико-социальных факторов). Диссертация доктора медицинских наук. Москва; 2011. 439 с.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Effektivnost' terapii shizofrenii atipichnymi neyroleptikami (znachenie razlichnyh kliniko-social'nyh faktorov). Dissertaciya doktora medicinskih nauk. Moskva; 2011. 439 s.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B26">
    <label>26.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Применение клозапина при лечении шизофрении. Москва, Новокузнецк: ОАО «Органика»; 2010. 48с.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Primenenie klozapina pri lechenii shizofrenii. Moskva, Novokuzneck: OAO «Organika»; 2010. 48s.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B27">
    <label>27.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Атипичный нейролептик клозапин (азалептин): спектр терапевтических эффектов и повторная оценка эффективности при лечении шизофрении. Социальнаяиклиническаяпсихиатрия. 2011;21(4):58-63.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Atipichnyy neyroleptik klozapin (azaleptin): spektr terapevticheskih effektov i povtornaya ocenka effektivnosti pri lechenii shizofrenii. Social'nayaiklinicheskayapsihiatriya. 2011;21(4):58-63.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B28">
    <label>28.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Данилов Д.С. Клозапин (азалептин): терапевтические возможности при лечении шизофрении. Современная терапия психических расстройств. 2012;(2):18-24.</mixed-citation>
     <mixed-citation xml:lang="en">Danilov D.S. Klozapin (azaleptin): terapevticheskie vozmozhnosti pri lechenii shizofrenii. Sovremennaya terapiya psihicheskih rasstroystv. 2012;(2):18-24.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B29">
    <label>29.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Chang J.S., Ahn Y.M., Park H.J., et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 May;69(5):720-31. doi: 10.4088/jcp.v69n0505</mixed-citation>
     <mixed-citation xml:lang="en">Chang J.S., Ahn Y.M., Park H.J., et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 May;69(5):720-31. doi: 10.4088/jcp.v69n0505</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B30">
    <label>30.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Cipriani А., Accordini S., Nosè M., et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol. 2013 Aug;33(4):533-7. doi: 10.1097/JCP.0b013e318296884f</mixed-citation>
     <mixed-citation xml:lang="en">Cipriani A., Accordini S., Nosè M., et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial. J Clin Psychopharmacol. 2013 Aug;33(4):533-7. doi: 10.1097/JCP.0b013e318296884f</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B31">
    <label>31.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Dold M., Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014 May;17(2):33-7. doi: 10.1136/eb-2014-101813</mixed-citation>
     <mixed-citation xml:lang="en">Dold M., Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014 May;17(2):33-7. doi: 10.1136/eb-2014-101813</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B32">
    <label>32.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Siskind D.J., Lee M., Ravindran A., et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018 Aug;52(8):751-67. doi:10.1177/0004867418772351</mixed-citation>
     <mixed-citation xml:lang="en">Siskind D.J., Lee M., Ravindran A., et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018 Aug;52(8):751-67. doi:10.1177/0004867418772351</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B33">
    <label>33.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Wagner E., Kane J.M., Correll C.U., et al. Clozapine combination and augmentation strategies in patients with schizophrenia – recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group. Schizophr Bull.2020 Dec;46(6):1459-70. doi: 10.1093/schbul/sbaa060</mixed-citation>
     <mixed-citation xml:lang="en">Wagner E., Kane J.M., Correll C.U., et al. Clozapine combination and augmentation strategies in patients with schizophrenia – recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group. Schizophr Bull.2020 Dec;46(6):1459-70. doi: 10.1093/schbul/sbaa060</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B34">
    <label>34.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Correll C.U., Rubio J.M., Inczedy-Farkas G., et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry.2017 Jul;74(7):675-84. doi:10.1001/jamapsychiatry.2017.0624</mixed-citation>
     <mixed-citation xml:lang="en">Correll C.U., Rubio J.M., Inczedy-Farkas G., et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry.2017 Jul;74(7):675-84. doi:10.1001/jamapsychiatry.2017.0624</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B35">
    <label>35.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kane J.M., Agid O., Baldwin M.L., et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019 Mar;80(2):18com12123. doi:10.4088/JCP.18com12123</mixed-citation>
     <mixed-citation xml:lang="en">Kane J.M., Agid O., Baldwin M.L., et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019 Mar;80(2):18com12123. doi:10.4088/JCP.18com12123</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B36">
    <label>36.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Barbui C., Accordini S., Nosè M., et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol. 2011 Jun;31(3):266-73. doi: 10.1097/JCP.0b013e318219cba3</mixed-citation>
     <mixed-citation xml:lang="en">Barbui C., Accordini S., Nosè M., et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol. 2011 Jun;31(3):266-73. doi: 10.1097/JCP.0b013e318219cba3</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B37">
    <label>37.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Nosè M., Accordini S., Artioli P., et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. 2009 May;10:31. doi: 10.1186/1745-6215-10-31</mixed-citation>
     <mixed-citation xml:lang="en">Nosè M., Accordini S., Artioli P., et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. 2009 May;10:31. doi: 10.1186/1745-6215-10-31</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B38">
    <label>38.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата Феназепам®, таблетки, диспергируемые в полости рта, РУ ЛП-№(005387)-(РГ-RU) от 07.05.2024.</mixed-citation>
     <mixed-citation xml:lang="en">Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Fenazepam®, tabletki, dispergiruemye v polosti rta, RU LP-№(005387)-(RG-RU) ot 07.05.2024.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B39">
    <label>39.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Середин С.Б., Воронина Т.А., Незнамов Г.Г., Жердев В.П.// Феназепам: 25 лет в медицинской практике, Москва: «Наука». – 2007.</mixed-citation>
     <mixed-citation xml:lang="en">Seredin S.B., Voronina T.A., Neznamov G.G., Zherdev V.P.// Fenazepam: 25 let v medicinskoy praktike, Moskva: «Nauka». – 2007.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
